Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A new era for fibrodysplasia ossificans progressiva: a druggable target for the second skeleton.

Expert opinion on biological therapy - 1 May 2007

Kaplan Frederick S, Glaser David L, Pignolo Robert J, Shore Eileen M

Abstract excerpt

Fibrodysplasia ossificans progressiva (FOP) is a disabling genetic condition that leads to the formation of a second (heterotopic) skeleton, and is the most catastrophic disorder of heterotopic ossification in humans. Throughout childhood and early adult life, FOP progressively immobilizes all of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Activin Receptors, Type I
Share to Bone Morphogenetic Proteins
Share to Disease Models, Animal

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Design

Share to Myositis Ossificans

Share to Ossification, Heterotopic

Share to Protein Kinase Inhibitors

Share to Transforming Growth Factor beta

Source

Identifiers

PMID: 17477807
DOI: 10.1517/14712598.7.5.705

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17477807-2026-09-02.1. Manifest publication-graph-cohort-2026-09-02.1.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A new era for fibrodysplasia ossificans progressiva: a druggable target for the second skeleton.PMID 17477807Read ↗

Fibrodysplasia ossificans progressiva.Semantic proximity Read ↗

From mysteries to medicines: drug development for fibrodysplasia ossificans progressivaSemantic proximity Read ↗

The Horizon of a Therapy for Rare Genetic Diseases: A “Druggable” Future for Fibrodysplasia Ossificans ProgressivaSemantic proximity Read ↗

Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans ProgressivaSemantic proximity Read ↗

Clinical Aspects and Current Therapeutic Approaches for FOPSemantic proximity Read ↗

Recent progress in drug development for fibrodysplasia ossificans progressiva.Semantic proximity Read ↗

Deregulated bone morphogenetic protein receptor signaling underlies fibrodysplasia ossificans progressiva.Semantic proximity Read ↗

Fibrodysplasia ossificans progressiva: a blueprint for metamorphosisSemantic proximity Read ↗

Novel Therapeutic Targets for Fibrodysplasia Ossificans Progressiva: Emerging Strategies and Future DirectionsSemantic proximity Read ↗

A Door Opens for Fibrodysplasia Ossificans Progressiva.Semantic proximity Read ↗

How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans ProgressivaSemantic proximity Read ↗

Fibrodysplasia ossificans progressiva emerges from obscurity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.